US2005084504A1PendingUtilityA1

Methods for treating various disorders with a neurotoxic component of a botulinum toxin

Assignee: ALLERGAN INCPriority: Dec 28, 1993Filed: Sep 2, 2004Published: Apr 21, 2005
Est. expiryDec 28, 2013(expired)· nominal 20-yr term from priority
A61P 29/00A61P 25/00A61P 21/02A61P 21/00A61P 19/02A61K 38/4893A61K 39/08Y02A50/30
64
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G.

Claims

exact text as granted — not AI-modified
1 . A method for reducing a cholinergic influenced secretion, said method comprising administering to a patient a therapeutically effective amount of a neurotoxic component of a  botulinum  toxin in order to reduce a cholinergic influenced the secretion.  
     
     
         2 - 5 . (canceled)  
     
     
         6 . method for treating a smooth muscle disorders, said method comprising administering to the patient a therapeutically effective amount of a neurotoxic component of a  botulinum  toxin in order to treat a smooth muscle disorder.  
     
     
         7 - 13 . (canceled)  
     
     
         14 . A method for relieving a muscle spasms said method comprising administering to a patient a therapeutically effective amount of a neurotoxic component of a  botulinum  toxin.  
     
     
         15 - 20 . (canceled)  
     
     
         21 . The method of  claim 1 , wherein the  botulinum  toxin is selected from the group consisting of  botulinum  toxin types A, B, C, D, E, F and G.  
     
     
         22 . The method of  claim 21 , wherein the  botulinum  toxin is a  botulinum  toxin type A.  
     
     
         23 . The method of  claim 6 , wherein the  botulinum  toxin is selected from the group consisting of  botulinum  toxin types A, B, C, D, E, F and G.  
     
     
         24 . The method of  claim 23 , wherein the  botulinum  toxin is a  botulinum  toxin type A.  
     
     
         25 . The method of  claim 14 , wherein the  botulinum  toxin is selected from the group consisting of  botulinum  toxin types A, B, C, D, E, F and G.  
     
     
         26 . The method of  claim 25 , wherein the  botulinum  toxin is a  botulinum  toxin type A.  
     
     
         27 . A neurotoxic component of a  botulinum  toxin for use in humans.  
     
     
         28 . the neurotoxic component of  claim 27 , wherein the neurotoxic component has a molecular weight of about 150 kilodaltons.  
     
     
         29 . the neurotoxic component of  claim 27 , wherein the neurotoxic component is selected from the group of consisting of  botulinum  toxin type A, B, C, D, E, F and G neurotoxic components.  
     
     
         30 . the neurotoxic component of  claim 29 , wherein the neurotoxic component is the neurotoxic component of a  botulinum  toxin type A.

Join the waitlist — get patent alerts

Track US2005084504A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.